Literature DB >> 26433115

Elevated miR-155 expression induces immunosuppression via CD39(+) regulatory T-cells in sepsis patient.

Jingquan Liu1, Kai Shi2, Minhua Chen3, Liang Xu3, Jun Hong3, Bangchuan Hu3, Xianghong Yang3, Renhua Sun4.   

Abstract

BACKGROUND: An altered microRNA profile exists in many infectious diseases, including sepsis. CD39(+) regulatory T-cells (Tregs) have a remarkable immunosuppressive effect and play an important role in the regulation of immune balance in sepsis. However, the correlation between microRNA changes and the ratio of CD39(+) Tregs in sepsis patients has not yet been reported. The altered microRNA expression profile in sepsis patients was analyzed in this study. Moreover, the correlation between microRNAs and disease severity and prognosis was investigated. Furthermore, the correlation between microRNAs and the percentage of peripheral blood CD39(+) Tregs was investigated and further verified in an animal model.
METHODS: Sixty sepsis patients and 30 healthy controls were included. The difference in microRNA expression was investigated by microRNA microarray and was further confirmed by real-time quantitative PCR. The correlations between microRNA changes and the Sepsis-related Organ Failure Assessment (SOFA) score, severity of sepsis, and survival were analyzed. The percentage CD39(+) Tregs in the peripheral blood of sepsis patients was measured by flow cytometry. The correlation between microRNAs and the percentage CD39(+) Tregs was analyzed and further confirmed in a mouse sepsis model.
RESULTS: Compared to healthy controls, sepsis patients exhibited a significantly elevated microRNA-155 (miR-155) level (p < 0.05), which was positively related to a higher SOFA score (r = 0.641, p < 0.05) and a greater severity of sepsis. The area under the receiver operating characteristic curve of miR-155 used for the prediction of 28-day survival was 0.763, with a cut-off point of 2.47. Patients with a miR-155 level >2.47 had a lower 28-day survival (p < 0.05). The miR-155 level of patients was proportional to the percentage of CD39(+) Tregs (r = 0.637, p < 0.05). After transfection with miR-155 inhibitor, the ratio of CD39(+) Tregs in mice with sepsis was significantly reduced (p < 0.05).
CONCLUSIONS: A higher level of miR-155 indicated a more severe condition and poorer prognosis in sepsis patients. The possible underlying mechanism could be that miR-155 induces an increased percentage of CD39(+) Tregs and thus immunosuppression.
Copyright © 2015 The Authors. Published by Elsevier Ltd.. All rights reserved.

Entities:  

Keywords:  MicroRNA; MicroRNA microarray; Outcome; Regulatory T-cell; Sepsis

Mesh:

Substances:

Year:  2015        PMID: 26433115     DOI: 10.1016/j.ijid.2015.09.016

Source DB:  PubMed          Journal:  Int J Infect Dis        ISSN: 1201-9712            Impact factor:   3.623


  27 in total

1.  MicroRNA-132, miR-146a, and miR-155 as potential biomarkers of methotrexate response in patients with rheumatoid arthritis.

Authors:  Ankita Singh; Pradeepta Sekhar Patro; Amita Aggarwal
Journal:  Clin Rheumatol       Date:  2018-12-03       Impact factor: 2.980

Review 2.  The Purinergic System as a Pharmacological Target for the Treatment of Immune-Mediated Inflammatory Diseases.

Authors:  Luca Antonioli; Corrado Blandizzi; Pál Pacher; György Haskó
Journal:  Pharmacol Rev       Date:  2019-07       Impact factor: 25.468

Review 3.  Role of microRNAs in sepsis.

Authors:  S Manoj Kumar Kingsley; B Vishnu Bhat
Journal:  Inflamm Res       Date:  2017-03-03       Impact factor: 4.575

Review 4.  Non-Coding RNA Networks as Potential Novel Biomarker and Therapeutic Target for Sepsis and Sepsis-Related Multi-Organ Failure.

Authors:  Domenico Di Raimondo; Edoardo Pirera; Giuliana Rizzo; Irene Simonetta; Gaia Musiari; Antonino Tuttolomondo
Journal:  Diagnostics (Basel)       Date:  2022-05-31

5.  Prognostic Effect of Adenosine-related Genetic Variants in Metastatic Colorectal Cancer Treated With Bevacizumab-based Chemotherapy.

Authors:  Ryuma Tokunaga; Shu Cao; Madiha Naseem; Jae Ho Lo; Francesca Battaglin; Alberto Puccini; Martin D Berger; Shivani Soni; Joshua Millstein; Wu Zhang; Sebastian Stintzing; Fotios Loupakis; Chiara Cremolini; Volker Heinemann; Alfredo Falcone; Heinz-Josef Lenz
Journal:  Clin Colorectal Cancer       Date:  2018-09-13       Impact factor: 4.481

Review 6.  MicroRNA: Crucial modulator in purinergic signalling involved diseases.

Authors:  Jing Guo; Peng Yang; Yi-Fan Li; Jin-Fan Tang; Zhao-Xuan He; Shu-Guang Yu; Hai-Yan Yin
Journal:  Purinergic Signal       Date:  2022-02-02       Impact factor: 3.765

Review 7.  The involvement of regulatory non-coding RNAs in sepsis: a systematic review.

Authors:  Jeffery Ho; Hung Chan; Sunny H Wong; Maggie H T Wang; Jun Yu; Zhangang Xiao; Xiaodong Liu; Gordon Choi; Czarina C H Leung; Wai T Wong; Zheng Li; Tony Gin; Matthew T V Chan; William K K Wu
Journal:  Crit Care       Date:  2016-11-28       Impact factor: 9.097

Review 8.  Non-coding RNA: a potential biomarker and therapeutic target for sepsis.

Authors:  Tie-Ning Zhang; Da Li; Jing Xia; Qi-Jun Wu; Ri Wen; Ni Yang; Chun-Feng Liu
Journal:  Oncotarget       Date:  2017-10-10

9.  IκK-16 decreases miRNA-155 expression and attenuates the human monocyte inflammatory response.

Authors:  Norman James Galbraith; James Burton; Mathew Brady Ekman; Joseph Kenney; Samuel Patterson Walker; Stephen Manek; Campbell Bishop; Jane Victoria Carter; Sarah Appel Gardner; Hiram C Polk
Journal:  PLoS One       Date:  2017-09-14       Impact factor: 3.240

10.  Are We Eating Our Way to Prostate Cancer-A Hypothesis Based on the Evolution, Bioaccumulation, and Interspecific Transfer of miR-150.

Authors:  Venkatesh Vaidyanathan; Vetrivhel Krishnamoorthy; Nishi Karunasinghe; Anower Jabed; Radha Pallati; Chi Hsiu-Juei Kao; Alice Wang; Gareth Marlow; Lynnette R Ferguson
Journal:  Noncoding RNA       Date:  2016-04-21
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.